Ford L C, Berek J S, Lagasse L D, Hacker N F, Heins Y, Esmailian F, Leuchter R S, DeLange R J
Gynecol Oncol. 1983 Jun;15(3):299-304. doi: 10.1016/0090-8258(83)90047-1.
The cytoplasmic receptors for 17 beta-estradiol (ER) and progesterone (PR) were measured in 39 malignant and 15 benign ovarian neoplasms. All eight endometroid carcinomas had positive ER sites, one-half contained PR. The number of ER binding sites decreased as tumor grade increased. Conversely, none of the 11 mucinous tumors contained either ER or PR receptors. One-half of the well-differentiated serous tumors had ER (57 +/- 23 fmole/mg protein) while none of the poorly differentiated tumors had measurable binding. In serous carcinomas, PR was only detected in well-differentiated lesions (447 +/- 240 fmole/mg protein). Only one of 15 benign neoplasms contained ER and PR receptors. Correlation of tumor grade and type may help to plan hormonal therapies in advanced ovarian malignancies.
在39例恶性和15例良性卵巢肿瘤中检测了17β-雌二醇(ER)和孕酮(PR)的细胞质受体。所有8例子宫内膜样癌均有ER阳性位点,其中一半含有PR。ER结合位点的数量随着肿瘤分级的增加而减少。相反,11例黏液性肿瘤均未含有ER或PR受体。一半高分化浆液性肿瘤有ER(57±23飞摩尔/毫克蛋白),而低分化肿瘤均无可测结合。在浆液性癌中,仅在高分化病变中检测到PR(447±240飞摩尔/毫克蛋白)。15例良性肿瘤中只有1例含有ER和PR受体。肿瘤分级与类型的相关性可能有助于制定晚期卵巢恶性肿瘤的激素治疗方案。